ASCO 2020：11项中国研究入选口头简报，17项Poster简报

深受世界最初冠鼠疫冲击，顺延于5月29日~6月2日在芝加哥开幕的旧金山诊疗该学会（ASCO）年会明年将首次以最初线上基本合办，这是目前最大规模的最初线上庆典。今天，决议的简述题目公布，共约103个sessions，中的国共约有11项数据比对入选为口头报告，17项入选为Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或莱切替尼加卡培他滨应用领域于HER2+高血压乳腺腺癌（PHOEBE）：一项III期随机实验。

专场：高血压乳腺腺癌

创作者：中的国医学科学院的医院徐兵河博士、马飞博士，复旦大学附属的医院胡夕春博士等

简述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴功能性乳腺腺癌标准用药后卡培他滨维持节拍低剂量的III期实验（SYSUCC-001）。

专场：乳腺腺癌—全局/区外/基本功能用药

创作者：中的山大学卫生保健区外内王为树森博士等

简述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用高血压大脑的表型特征来得出尿素系统中的尿素DNA检验的概率: 最初应用领域软件对抗老对手

专场：最初应用领域软件克服老问题

创作者：李美芹 李科克等

简述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为后半期肝脏巨噬细胞腺癌的主干最初线用药：一项开放日标签、随机、多区外内II/III期实验。

专场：食道肠道腺癌—食道静脉、胰腺和肝脏胆

创作者：四川大学棱果的医院毕锋博士、中的国祖国解放军淮海的医院秦叔逵博士等

简述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中的国后半期肝脏腺癌病征阿帕替尼主干最初线用药：一项随机、疗效依此、双盲III期数据比对

专场：食道肠道腺癌—食道静脉、胰腺和肝脏胆

创作者：中的国祖国解放军淮海的医院秦叔逵博士、四川大学棱果的医院李秋博士等

简述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后半期患功能性卵巢腺癌二次巨噬细胞减灭术的一项随机III期实验：SOC1 / SGOG-OV2。

专刊：妇产科腺结核病

创作者：复旦大学附属中的山的医院臧荣余博士等

简述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈腺癌根治功能性子宫切除术后基本功能用药中的的序贯放低剂量对比单独化学疗法或启动时放低剂量（STARS数据比对）：一项随机、依此、开放日标签的III期实验。

决议：妇产科腺结核病

创作者：中的山大学卫生保健区外内黄鹤博士、刘继红博士等

简述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：基本功能吉非替尼对比低剂量应用领域于可切除的EGFR功能性状的N1-N2期NSCLC-随机III期诊疗实验的最终总体生存比对。

专刊：心肌梗塞—非小巨噬细胞全局-区外/小巨噬细胞/其他腰部

创作者：广东省祖国的医院吴一龙博士等

简述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR功能性状寡转移非小巨噬细胞心肌梗塞病征主干最初线代谢物还原酶类固醇联合行动或不联合行动积极的部队全局化学疗法：III期开放日标签诊疗随机实验（SINDAS）的中的期结果（NCT02893332）。

专刊：心肌梗塞-非小巨噬细胞转移

创作者：泸州祖国的医院曾铭博士等

简述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序功能性死亡-1（PD-1）的人源化IgG4酵母联合行动阿昔替尼应用领域于高血压黏膜食道癌病征的Ib期数据比对的总生存期和生物圣万比对。

专刊：食道癌/皮肤腺癌

创作者：北京大学的医院郭军、盛锡楠博士等

简述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的稳定功能性和结果：国际标准CAR-T巨噬细胞首次人体实验用药患/难治功能性T巨噬细胞急功能性淋巴巨噬细胞胃癌（r/r T-ALL）的稳定功能性和。决议：开发中的的用药高效率-免疫用药。创作者：王为欣欣等简述：3013贴纸：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在后半期静脉鳞状巨噬细胞腺癌病征中的的应用领域：一项随机的开放日标签II期实验（ORIENT-2）。决议：食道肠道腺癌-食道静脉腺癌、胰腺腺癌和肝脏胆道腺癌创作者：徐建明博士等简述：4511贴纸：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异功能性CAR-T巨噬细胞对髓母巨噬细胞瘤的消弭功能性用药决议：中的枢神经系统创作者：代红久、孙斌、杨东、徐晖、徐美美、魏佳、赵旭东简述：2522贴纸。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后半期错配修复不足之处病征中的的应用领域决议：开发中的的用药学-免疫用药创作者：沈琳博士等简述：3021贴纸。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART用药患/难治功能性ACUTE淋巴巨噬细胞胃癌/结核病的首例人体诊疗实验决议: 开发功能性用药学-免疫用药创作者简介：张明志，白水等简述：3026贴纸: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度羟基（T）联合行动广泛应用领域后半期实体瘤病征的Ib期数据比对决议：发展功能性用药学--分子靶向抗生素和生物学创作者：龚继芳，沈琳博士等简述：3523贴纸：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin联合行动制剂和nedaplatin用药患功能性或高血压静脉鳞状巨噬细胞腺癌（ESCC）病征的II期数据比对。决议：食道肠道腺癌-食道静脉、胰腺和肝脏胆道腺癌的数据比对创作者：王为志强，李玉红，王为德申，王为凤华，任超，谭琼 王为志强、李玉红、王为德深、王为凤华、任超、谭琼简述：4522贴纸：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.决议：食道肠道腺癌-食道静脉腺癌、胰腺腺癌和肝脏胆管腺癌的主干最初线用药创作者：宋艳等简述：4524贴纸：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种血液外体放射状RNA分类器应用领域于初始活检时检验高等级腺癌的血液外体放射状RNA分类器：一项多区外内的回顾功能性数据比对决议：泌尿生殖系统腺结核病----腺癌、睾丸腺癌和腺癌创作者简介：Liaoyuan Li等简述：5522贴纸。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 全局后半期宫颈腺癌并发低剂量后的基本功能低剂量决议: 妇产科腺结核病创作者简介： 李珉珉等简述：6031贴纸：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼用药甲状腺髓功能性腺癌的相关功能性：基于ALTER01031实验的比对。会话：多毛创作者：长春市的医院老练博士简述：6526贴纸。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年长对安洛替尼用药后病征上集的冲击: ALTER01031的亚组比对决议：多毛创作者：长春市的医院老练博士简述：6527贴纸。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA比对得出I-IIIA期非小巨噬细胞心肌梗塞（NSCLC）病征术后患: GASTO1035和GASTO1018的结果决议：心肌梗塞-非小巨噬细胞全局-区外功能性/小巨噬细胞/小巨噬细胞/其他胸科腺结核病创作者：Si-Yu Wang等简述：9023贴纸：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小巨噬细胞心肌梗塞（NSCLC）中的EGFR代谢物还原酶类固醇的最初型青霉素机制决议:心肌梗塞-非小巨噬细胞高血压心肌梗塞创作者简介：赵昕，金结缘，满宇，欧元人，梅氏，薛武，杨少，范敏 赵昕、金结缘、满宇、欧元人、梅氏、薛武、杨绍、范敏简述：9528贴纸：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1实验中的后半期食道癌总生存的替代往北决议：食道癌/皮肤腺癌创作者：聂润聪，袁书强，李元芳，陈英波，周志伟 聂润聪、袁书强、李元芳、陈英波、周志伟简述：10030贴纸：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼用药患或高血压细菌功能性恶功能性骨病征的II期数据比对决议： 畸形创作者：唐丽娜，牛晓辉，王为震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王为振、蔡启庆、涂崇奇、范正福、杨瑶简述：11525贴纸。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步称赞安罗替尼在后半期畸形病征多最初线用药中的的稳定功能性和。决议：畸形创作者：姚伟涛，陈家强，玑，王为欣，杜最初辉，田志浩，牛晓颖 姚伟涛、陈家强、玑、王为鑫、杜鑫辉、田志超、牛晓英简述：11526贴纸：414